Cellectar Biosciences announced positive 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, showing an 83.6% overall response rate and median response duration of 17.8 months. The data meet FDA requirements for accelerated approval and support a confirmatory trial planned for late 2026. The drug showed strong efficacy in patients previously treated with BTK inhibitors, a difficult-to-treat group, and maintained a manageable safety profile. This progress positions iopofosine I 131 as a promising new treatment option for heavily pretreated WM patients with limited alternatives.
Basel Medical Group Ltd announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 10 consecutive business days ending July 7, 2026. The company was previously notified in January 2026...
The global wax market, valued at $11.26 billion in 2025, is projected to grow to $16.65 billion by 2035 at a CAGR of 3.99%. Growth is fueled by rising demand in packaging, cosmetics, candle making, adhesives, and industrial uses, with natural waxes l...
BingX, a major crypto exchange, introduced the BingX Visa Debit Card in partnership with Wirex, allowing users to spend digital assets globally through Visa's payment network. The card supports purchases, ATM withdrawals, and automatic currency conve...
Backpack has introduced the first-ever 24/7 trading platform for real U.S. equities, allowing international investors to buy and sell stocks like SpaceX, Micron, and SanDisk around the clock. Unlike synthetic derivatives, these are actual equities wi...
Independent proxy advisory firms, including ISS, recommend Equinox Gold shareholders vote in favor of the proposed merger with Orla Mining, which aims to create a leading North American gold producer. The combined company is expected to produce 1.1 m...
